+1 Recommend
    • Review: found
    Is Open Access

    Review of 'Apolipoprotein C-III's role in cardiovascular diseases, a short review.'

    Apolipoprotein C-III's role in cardiovascular diseases, a short review.Crossref
    An interesting brief review regarding ApoC-III, but written in poor language and not well justified.
    Average rating:
        Rated 2 of 5.
    Level of importance:
        Rated 2 of 5.
    Level of validity:
        Rated 3 of 5.
    Level of completeness:
        Rated 2 of 5.
    Level of comprehensibility:
        Rated 1 of 5.
    Competing interests:

    Reviewed article

    • Record: found
    • Abstract: found
    • Article: found
    Is Open Access

    Apolipoprotein C-III's role in cardiovascular diseases, a short review.

    In this short review we show the important role played by apoC-III in the lipid dysregulation present in the majority of cardiovascular diseases. With emphasis on the mutations present in a minority of individuals that confer protection. With this in mind we state that apoC-III should be considered a valid target for pharmaceutical intervention and cardiovascular disease control and progression.

      Review information

      Review text

      In this article, Dr Olteanu presents a short overview of the available literature on the role of ApoC-III in CVD. The author also offers insight in the metabolic pathways and the mutations of ApoC-III and remarks their clinical impact. It is a useful mini review, since it refers to a marker that is not measured in everyday clinical practice, but it is accompanied with significant clinical manifestations regarding CVD. However, I feel that there are several concerns that need to be taken into consideration. These are the following:

      Major Concerns
      The entire manuscript needs to be re-organized and re-written due to several serious errors in composition, syntax and grammar. Moreover, it is also recommended that it is thoroughly edited by a scientific writer/editor.
      The author concludes that ApoC-III could be a potential target for a number of novel drugs. However, drugs such as statins, fibrates, ezetimibe, etc that are reported to be related with lower levels of ApoC-III are not mentioned in the “discussion” section.
      In order to elucidate the role of ApoC-III in CVD, there are more to be mentioned than just ApoC-III mutations. There are several clinical studies that report correlation between ApoC-III and cardiovascular events which deserve to be highlighted.
      Apart from VLDL and LPL, ApoC-III also interacts with β-integrin, ICAM-I, VCAM-I. These molecules also play a significant role in CVD progression. Thus, they should not be omitted.

      Minor Concerns
      The article title could be changed to “Apolipoprotein C-III’s role in cardiovascular diseases: A brief review”.
      In “ApoC-III SUMMARY” please specify which enteric cells participate in the excretion of ApoC-III.

      Moreover, a more extensive review that sheds light on various aspects of the link between ApoC-III and CVD is the following “OOI et al. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clinical Science 2008;114:611-624”. Thus, it is my firm belief that it should be included in the references.


      Comment on this review